Lex­i­con shares surge as Sanofi touts pos­i­tive PhI­II for their new di­a­betes drug

Shares of Lex­i­con Phar­ma ($LXRX) popped and then fad­ed some­what Fri­day morn­ing af­ter the biotech and its Big Phar­ma part­ners at Sanofi en­thused over pos­i­tive da­ta from a Phase III study of their di­a­betes drug so­tagliflozin.

Billed as a next-gen im­prove­ment on the SGLT2 ap­proach to flush­ing blood sug­ar through urine, in­ves­ti­ga­tors say that two dos­es of their drug were able to re­duce A1C lev­els by 0.43% and 0.49% in Type 1 pa­tients, far bet­ter than the 0.08% re­duc­tion seen in the place­bo group.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER